# EVOKE-01 (NCT05089734)

> Study of Sacituzumab Govitecan (SG) Versus Docetaxel in Participants With Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT05089734
- Phase: PHASE3
- Status: ACTIVE_NOT_RECRUITING
- Sponsor: Gilead Sciences
- Conditions: Non-Small Cell Lung Cancer
- Interventions: Sacituzumab Govitecan-hziy (SG); Docetaxel
- Enrollment: 603
- Primary outcome: Overall Survival (OS)

## Commentary we found

- X threads: 64
- YouTube: 20
- Podcasts: 18

## Order

Deep, $1,950, price fixed at order: https://www.erudio.com/contact?report=evoke-01-nct05089734

## Free build

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT05089734", "email": "<work email>"}; the inbox owner confirms by the emailed link.